Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
about
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewDapagliflozin for the treatment of type 2 diabetes: a review of the literatureEffect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
P2860
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@en
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@nl
type
label
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@en
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@nl
prefLabel
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@en
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@nl
P2093
P2860
P356
P1476
Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
@en
P2093
Andrew Aylsworth
Arinze Nkemdirim Okere
Cody VanNorman
Zachary Dean
P2860
P304
P356
10.1177/1060028014540450
P407
P577
2014-06-20T00:00:00Z